Loading clinical trials...
Loading clinical trials...
The purpose of this study is to find out more about the long-term safety of pirtobrutinib in participants with previously treated types of blood cancer. Participants must have chronic lymphocytic leuk...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
1-317-615-4559LillyTrials@Lilly.comPhysicians interested in becoming principal investigators please contact
CONTACT
clinical_inquiry_hub@lilly.comLead Sponsor
Eli Lilly and Company
NCT05272384 · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, and more
NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more
NCT05139017 · DLBCL, Diffuse Large B-Cell Lymphoma
NCT06026319 · Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, and more
NCT06510361 · Lymphoma, Follicular Lymphoma, and more
Beijing Cancer hospital
Beijing
Sun Yat-sen University Cancer Center
Guangzhou
Harbin Medical University Cancer Hospital
Harbin
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions